Menu
Search
|

Menu

Close
X

argenx SE ARGX.OQ (NASDAQ Stock Exchange Global Select Market)

126.74 USD
+0.00 (+0.00%)
As of Feb 15
chart
Previous Close 126.74
Open 117.54
Volume 141,429
3m Avg Volume 61,580
Today’s High 126.84
Today’s Low 117.15
52 Week High 126.84
52 Week Low 63.81
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.70 Mean rating from 10 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.99
Price to Sales (TTM)
vs sector
--
10.11
Price to Book (MRQ)
vs sector
--
4.60
Price to Cash Flow (TTM)
vs sector
--
26.60
Total Debt to Equity (MRQ)
vs sector
--
16.95
LT Debt to Equity (MRQ)
vs sector
--
13.45
Return on Investment (TTM)
vs sector
--
12.72
Return on Equity (TTM)
vs sector
--
13.73

EXECUTIVE LEADERSHIP

Peter Verhaeghe
Non-Executive Chairman of the Board, Since 2014
Salary: --
Bonus: --
Tim Van Hauwermeiren
Chief Executive Officer, Member of the Board, Since 2014
Salary: €303,941.00
Bonus: --
Werner Lanthaler
Non-Executive Vice Chairman of the Board, Since 2014
Salary: --
Bonus: --
Eric Castaldi
Chief Financial Officer, Since 2014
Salary: €271,344.00
Bonus: --
Hans de Haard
Chief Scientific Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Willemstraat 5
BREDA     4811 AH

Phone: +3176.3030488

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

SPONSORED STORIES